Clinical Significance of TAP1 and DLL4 Expression in Patients With Locally Advanced Gastric Cancer

xlomafota13 shared this article with you from Inoreader Clinical Significance of TAP1 and DLL4 Expression in Patients With Locally Advanced Gastric Cancer Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2771-2777. doi: 10.21873/invivo.12562. ABSTRACT BACKGROUND/AIM: Cancer stem cells (CSCs) are reported to associated with cancer metastasis, relapse, and chemoresistance. This study examined the clinical significance of the expression of two CSC markers, the transporter associated with antigen processing 1 (TAP1) and the Delta-like 4 (DLL4) protein, in patients with locally advanced GC. PATIENTS AND METHODS: This study was performed using samples obtained from 413 pathological stage II/III GC patients after curative gastrectomy. We examined TAP1 and DLL4 expression using immunohistochemical analysis with tissue microarray and examined the association between TAP1 or DLL4 expression, clinicopathological factors and survival. RESULTS: High TAP1 expression was associated with better overall survival compared to low TAP1 expression (p=0.004). Furthermore, in multivariate analysis, high TAP1 expression was defined as a predictive factor for good survival. There was no significant difference between DLL4 expression and clinicopathological features and overall survival. CONCLUSION: TAP1 expression may be a useful prognostic marker in patients with locally advanced GC. PMID:34410967 | DOI:10.21873/invivo.12562 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.